Contrasting benefits of different artemisinin combination therapies as first-line malaria treatments using model-based cost-effectiveness analysis
© 2014 Macmillan Publishers Limited. All rights reserved. There are currently several recommended drug regimens for uncomplicated falciparum malaria in Africa. Each has different properties that determine its impact on disease burden. Two major antimalarial policy options are artemether-lumefantrine...
Saved in:
Main Authors: | , , , , , , , , , , , |
---|---|
Other Authors: | |
Format: | Article |
Published: |
2018
|
Subjects: | |
Online Access: | https://repository.li.mahidol.ac.th/handle/123456789/33510 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Mahidol University |
id |
th-mahidol.33510 |
---|---|
record_format |
dspace |
spelling |
th-mahidol.335102018-11-09T10:15:11Z Contrasting benefits of different artemisinin combination therapies as first-line malaria treatments using model-based cost-effectiveness analysis Lucy C. Okell Matthew Cairns Jamie T. Griffin Neil M. Ferguson Joel Tarning George Jagoe Pierre Hugo Mark Baker Umberto D'Alessandro Teun Bousema David Ubben Azra C. Ghani Imperial College London London School of Hygiene & Tropical Medicine Nuffield Department of Clinical Medicine Mahidol University Medicines for Malaria Venture Prince Leopold Institute of Tropical Medicine Medical Research Council Unit Radboud University Nijmegen Medical Centre Biochemistry, Genetics and Molecular Biology Chemistry Physics and Astronomy © 2014 Macmillan Publishers Limited. All rights reserved. There are currently several recommended drug regimens for uncomplicated falciparum malaria in Africa. Each has different properties that determine its impact on disease burden. Two major antimalarial policy options are artemether-lumefantrine (AL) and dihydroartemisinin-piperaquine (DHA-PQP). Clinical trial data show that DHA-PQP provides longer protection against reinfection, while AL is better at reducing patient infectiousness. Here we incorporate pharmacokinetic-pharmacodynamic factors, transmission-reducing effects and cost into a mathematical model and simulate malaria transmission and treatment in Africa, using geographically explicit data on transmission intensity and seasonality, population density, treatment access and outpatient costs. DHA-PQP has a modestly higher estimated impact than AL in 64% of the population at risk. Given current higher cost estimates for DHA-PQP, there is a slightly greater cost per case averted, except in areas with high, seasonally varying transmission where the impact is particularly large. We find that a locally optimized treatment policy can be highly cost effective for reducing clinical malaria burden. 2018-11-09T02:01:26Z 2018-11-09T02:01:26Z 2014-01-01 Article Nature Communications. Vol.5, (2014) 10.1038/ncomms6606 20411723 2-s2.0-84923377601 https://repository.li.mahidol.ac.th/handle/123456789/33510 Mahidol University SCOPUS https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84923377601&origin=inward |
institution |
Mahidol University |
building |
Mahidol University Library |
continent |
Asia |
country |
Thailand Thailand |
content_provider |
Mahidol University Library |
collection |
Mahidol University Institutional Repository |
topic |
Biochemistry, Genetics and Molecular Biology Chemistry Physics and Astronomy |
spellingShingle |
Biochemistry, Genetics and Molecular Biology Chemistry Physics and Astronomy Lucy C. Okell Matthew Cairns Jamie T. Griffin Neil M. Ferguson Joel Tarning George Jagoe Pierre Hugo Mark Baker Umberto D'Alessandro Teun Bousema David Ubben Azra C. Ghani Contrasting benefits of different artemisinin combination therapies as first-line malaria treatments using model-based cost-effectiveness analysis |
description |
© 2014 Macmillan Publishers Limited. All rights reserved. There are currently several recommended drug regimens for uncomplicated falciparum malaria in Africa. Each has different properties that determine its impact on disease burden. Two major antimalarial policy options are artemether-lumefantrine (AL) and dihydroartemisinin-piperaquine (DHA-PQP). Clinical trial data show that DHA-PQP provides longer protection against reinfection, while AL is better at reducing patient infectiousness. Here we incorporate pharmacokinetic-pharmacodynamic factors, transmission-reducing effects and cost into a mathematical model and simulate malaria transmission and treatment in Africa, using geographically explicit data on transmission intensity and seasonality, population density, treatment access and outpatient costs. DHA-PQP has a modestly higher estimated impact than AL in 64% of the population at risk. Given current higher cost estimates for DHA-PQP, there is a slightly greater cost per case averted, except in areas with high, seasonally varying transmission where the impact is particularly large. We find that a locally optimized treatment policy can be highly cost effective for reducing clinical malaria burden. |
author2 |
Imperial College London |
author_facet |
Imperial College London Lucy C. Okell Matthew Cairns Jamie T. Griffin Neil M. Ferguson Joel Tarning George Jagoe Pierre Hugo Mark Baker Umberto D'Alessandro Teun Bousema David Ubben Azra C. Ghani |
format |
Article |
author |
Lucy C. Okell Matthew Cairns Jamie T. Griffin Neil M. Ferguson Joel Tarning George Jagoe Pierre Hugo Mark Baker Umberto D'Alessandro Teun Bousema David Ubben Azra C. Ghani |
author_sort |
Lucy C. Okell |
title |
Contrasting benefits of different artemisinin combination therapies as first-line malaria treatments using model-based cost-effectiveness analysis |
title_short |
Contrasting benefits of different artemisinin combination therapies as first-line malaria treatments using model-based cost-effectiveness analysis |
title_full |
Contrasting benefits of different artemisinin combination therapies as first-line malaria treatments using model-based cost-effectiveness analysis |
title_fullStr |
Contrasting benefits of different artemisinin combination therapies as first-line malaria treatments using model-based cost-effectiveness analysis |
title_full_unstemmed |
Contrasting benefits of different artemisinin combination therapies as first-line malaria treatments using model-based cost-effectiveness analysis |
title_sort |
contrasting benefits of different artemisinin combination therapies as first-line malaria treatments using model-based cost-effectiveness analysis |
publishDate |
2018 |
url |
https://repository.li.mahidol.ac.th/handle/123456789/33510 |
_version_ |
1763488437356199936 |